Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gregory D. Gorgas
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Beta
- -0.07
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -12.69
Financials
Net Income
$-1.77MEBITDA
$-1.77MFree Cash Flow
$-2.63MEPS (diluted)
$-3.19Shares Outstanding (diluted)
554.2K+15568.6%Operating Expenses
$1.79MCash & Debt
$4.44MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.88M | $-49.23 |
| 2024 | $0.00 | $-9.83M | $-9.15 |
| 2023 | $0.00 | $-9.29M | $-9.42 |
| 2022 | $0.00 | $-10.08M | $-10.47 |
| 2020 | $0.00 | $-7.44M | $-17.91 |
| 2019 | $0.00 | $-4.66M | $-56.48 |
| 2018 | $0.00 | $-2.17M | $-45.00 |
| 2017 | $0.00 | $-2.34M | $-82.55 |
| 2016 | $0.00 | $-234.9K | $-9.69 |
| 2015 | $0.00 | $-29.7K | $-1.41 |
| 2014 | $0.00 | $-15.2K | $-0.72 |
| 2013 | $0.00 | $-15.3K | $-1.80 |
Valuation
ARTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·10d ago·Positive
…s Provides Business Update and Reports 2026 Third Quarter Financial Results SOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, obesity, dermatologic, ophthalmic, and neurological conditions, today provided a business update and announced its financial and operational results for …
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
…o evaluate ART27.13's potential to address multiple cancer-related symptoms SOLANA BEACH, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that it will present data demonstrating the potential of ART27.13 to treat chemotherap…
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
View source ↗ - Newsglobenewswire.com·94d ago·Positive
…apan for Patent Claims for the Intended Commercial Formulation of ART27.13 SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Gran…
View source ↗ - Newsglobenewswire.com·97d ago·Neutral
…of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering…
View source ↗
Earnings
Wed, Mar 31(in 4 months)
Consensus estimate $-7.83 per share
Typical surprise -41.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-3.19 vs $-7.02beat
- Wed, Aug 12$-8.01 vs $-6.48miss
- Thu, May 14$-4.00 vs $-0.78miss
- Tue, Feb 24$-6.66 vs $-4.71miss
- Wed, Nov 12$-11.91 vs $-2.46miss
- Tue, Aug 12$-16.83 vs $-12.57miss
Estimates and results for ARTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARTL officers and directors.
No open-market trades in the recent filings. All 97 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARTL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
